Skip to main content
ALPROLIX® logo

Resources for Patients


Over a decade of dedication: our unwavering commitment to you and your patients

ALPROLIX Patient Brochure 

If your patient or their caregiver is interested in learning more about the data, safety, and pharmacokinetics of ALPROLIX, this brochure has the details.

patient brochure
Download Patient Brochure

Patient Support from Sanofi Support | HemAssist

We surround ALPROLIX patients with access, support, and education from HemAssist Sanofi Support.

When you're living with hemophilia, you may need support on your side. HemAssist provides patients and their caregivers with the support they may need along their treatment journey.

This includes:

FINANCIAL ASSISTANCE

Financial Assistance

Every person’s situation is different, which is why we work directly with patients to help identify the financial assistance programs for which they may be eligible.

TREATMENT EDUCATION

Treatment Education

We can help your patients understand more about ALPROLIX, as well as offer supplemental administration training and tips to help them start and stay on track with treatment as prescribed.

ACCESS TO TREATMENT

icon

From navigating insurance coverage to assisting with reimbursement, our team works with you and your patients to get them started on ALPROLIX as efficiently as possible.

logo

Patient support from HemAssist

We're here for you. Discover how Sanofi patient support from HemAssist can help.

Financial assistance programs

COPAY ASSISTANCE PROGRAM*

financial support icon

HemAssist may be able to help eligible ALPROLIX® patients gain access to treatment for as little as $0.

FREE TRIAL PROGRAM*

free trial icon

Patients prescribed ALPROLIX for the first time can receive their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription.

PATIENT ASSISTANCE PROGRAM

patient assistance

HemAssist Sanofi Support may be available to help eligible uninsured and underinsured patients.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALPROLIX prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALPROLIX prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

HemAssist Patient Enrollment Form

Complete the form with your patient to enroll them in HemAssist, the patient support program for ALPROLIX

Help patients find their CoRe Manager and connect today

Sanofi Hemophilia Community Relations and Education (CoRe) Managers provide education and support to people living with hemophilia and their families. This includes explaining treatment options, but also lifestyle tips and events in your area. Use our CoRe Locator to find the CoRe Manager nearest your patient.

Find local CoRes

Patients can manage their hemophilia with the help of MicroHealth tracking

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia.

Learn more about MicroHealth

Google Play and the Google Play logo are trademarks of Google LLC.
Apple and the Apple logo are trademarks of Apple Inc. App Store is a service mark of Apple Inc.

Interface of a hemophilia management app, MicroHealth, featuring user details and menu options like treatment and messages.

Hemophilia B Advocacy Groups

This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites. These listings do not constitute an endorsement by Sanofi of information provided by any other organizations.

The Coalition for Hemophilia BNational Hemophilia FoundationHemophilia Federation of AmericaWorld Federation of Hemophilia
calendar icon

Request more information or a meeting with an ALPROLIX representative

INDICATION:

ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS:

The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

INDICATION:

IMPORTANT SAFETY INFORMATION

©2025 Sanofi. All rights reserved. ALPROLIX, Sanofi, and HemAssist are trademarks or registered trademarks of Sanofi or an affiliate. All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi. MAT-US-2021406-v11.0-10/2025 Last updated: October 2025